Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.Ulocplumab inhibits the migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation, induces apoptosis, and inhibits the growth and migration of cancer cells. Ulocplumab inhibits CXCL12-mediated chronic lymphocytic leukemia (CLL) cell migration in response to CXCR4 activation and induces apoptosis.)

Ramos cells:10 nM

Ulocuplumab (0-100 μM; 48 h) lacks antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity. However, it induces CXCR4-binding-mediated apoptosis in Ramos cells and CLL or cancer cell lines. It also demonstrates pro-apoptotic effects in primary leukemia cells from CLL patients [1].
Ulocuplumab (0.2 μM, 2 μM; 15 s) inhibits F-actin polymerization, reduces peak responses to CXCL12, and (20 nM-2 μM; 1 h) additionally inhibits cell migration [1].
At a concentration of 200 nM for 6 hours, Ulocuplumab induces programmed cell death (PCD) independently of caspases [1].
Ulocuplumab (10 μg/mL; 4 h) induces cell death in CLL cells by generating reactive oxygen species (ROS) [1].
Ulocuplumab inhibits CXCL12-induced calcium flux, with an EC50 of 10 nM in Ramos cells [2].

Ulocuplumab (3-30 mg/kg; intraperitoneal injection; 5 doses over 3-4 days; a total of 65 days) inhibits tumor growth in a murine multiple myeloma xenograft model, including tumor models with Ramos B cells, HL-60 cells, MOLP-8 cells, Nomo-1 cells, and JJN-3R cells [1].

Human

Monoclonal

Unconjugated